Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

7.410 -0.020 (-0.27%)
Delayed Quote Updated: 9:35 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,421
Open 7.510
Bid (Size) 7.400 (200)
Ask (Size) 7.420 (100)
Prev. Close 7.430
Today's Range 7.410 - 7.520
52wk Range 6.970 - 14.51
Shares Outstanding 63,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arvinas Inc.
Via GlobeNewswire

Performance

YTD
-35.4%
-35.4%
1 Month
-20.2%
-20.2%
3 Month
-11.7%
-11.7%
6 Month
-31.7%
-31.7%
1 Year
-18.8%
-18.8%

More News

Read More
News headline image
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas (NASDAQ:ARVN) Q1 2026 Results: First-Ever PROTAC Approval Offsets Revenue Miss ↗
Via Chartmill
Arvinas Inc (NASDAQ:ARVN) Stock Plummets After Q4 2025 Earnings and Revenue Miss Estimates ↗
Via Chartmill
News headline image
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas (ARVN) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Arvinas Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Transcript: Arvinas Q2 2026 Earnings Conference Call ↗
Via Benzinga
Topics Earnings
News headline image
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data ↗
Via MarketBeat
News headline image
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present at Jefferies Global Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Employees Give Back During Company-wide Impact Day
From Arvinas Inc.
Via GlobeNewswire
News headline image
These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗
Via Benzinga
News headline image
Arvinas Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Arvinas, Inc. - Common Stock publicly traded?
Yes, Arvinas, Inc. - Common Stock is publicly traded.
What exchange does Arvinas, Inc. - Common Stock trade on?
Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arvinas, Inc. - Common Stock?
The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market
What is the current price of Arvinas, Inc. - Common Stock?
The current price of Arvinas, Inc. - Common Stock is 7.410
When was Arvinas, Inc. - Common Stock last traded?
The last trade of Arvinas, Inc. - Common Stock was at 10/02/26 09:35 AM ET
What is the market capitalization of Arvinas, Inc. - Common Stock?
The market capitalization of Arvinas, Inc. - Common Stock is 470.54M
How many shares of Arvinas, Inc. - Common Stock are outstanding?
Arvinas, Inc. - Common Stock has 471M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.